Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA9 | P38646 | 4/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11513619 | 0.81 | HSPA9 (0.42) | HSPA9NQO2MEN1MAPTKMT2A | |
| SCHEMBL11810345 | 0.80 | RARB (0.44) | HSPA9MEN1MAPTKMT2APDK2 | |
| SCHEMBL9382451 | 0.79 | HDAC3 (0.65) | HSPA9NQO2MAOAPOLBMEN1 | |
| SCHEMBL9380015 | 0.78 | CA12 (0.47) | MAOAPOLBMEN1MAPTKMT2A | |
| SCHEMBL3935697 | 0.74 | RARB (0.64) | MAOAPOLBMEN1MAPTKMT2A | |
| SCHEMBL10696147 | 0.74 | NQO2 (0.61) | NQO2MAOAPOLBMEN1MAPT | |
| SCHEMBL31456579 | 0.73 | RARB (0.53) | POLBMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL11513542 | 0.73 | MEN1 (0.55) | NQO2MAOAPOLBMEN1MAPT | |
| SCHEMBL29549395 | 0.71 | MEN1 (0.52) | NQO2POLBMEN1MAPTKMT2A | |
| SCHEMBL3150642 | 0.71 | HDAC3 (0.52) | NQO2MAOAPOLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7026476-B2 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7019006-B2 | Modulating release of inflammatory cytokines by administering, e.g., a 1-(5-tert-butyl-2-methyl-phenyl)-3-(6-((3-methoxy-propyl)-methylaminopyridin-3-yl)phthalen-1-yl) urea or thiourea; treating a neutrophil-mediated disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1165516-B1 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030225077-A1 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6656933-B2 | Novel compounds which inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1165516-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000055139-A2 | HETEROCYCLIC UREA AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| US-4863945-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0271040-A2 | Pyrrolobenzimidazoles, process for their preparation, and medicaments | Roche Diagnostics GmbH (DE) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225077-A1 | Intermediate arylamine compounds | AHR, AADAC, NAT1 | HSPA9 2155/4885NQO2 666/4885MAOA 62/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | HSPA9 1186/4885NQO2 1039/4885MAOA 680/4885 |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | HSPA9 1186/4885NQO2 1039/4885MAOA 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.